The non-GH deficiency disorders of Noonan syndrome and idiopathic short stature have also received approval for GH use from the FDA, but not the EMA, and short stature due to SHOX gene haploinsufficiency and Prader-Willi syndrome (PWS) have received approval for some GH formulations in some countries (2,3,4). This evidence concerns the gene SHOX and Prader-Willi syndrome.